These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31872374)

  • 21. The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs.
    Bjersing JL; Eriksson K; Tarkowski A; Collins LV
    Inflammation; 2004 Feb; 28(1):39-51. PubMed ID: 15072229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
    Adamsson J; Lindblad M; Lundqvist A; Kelly D; Holmgren J; Harandi AM
    J Immunol; 2006 Apr; 176(8):4902-13. PubMed ID: 16585586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CpG oligodeoxynucleotides activate grass carp (Ctenopharyngodon idellus) macrophages.
    Meng Z; Shao J; Xiang L
    Dev Comp Immunol; 2003 Apr; 27(4):313-21. PubMed ID: 12590965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of immunostimulatory oligodeoxynucleotide from Escherichia coli genomic DNA.
    Choi YJ; Lee KW; Kwon HJ; Kim DS
    J Biochem Mol Biol; 2006 Nov; 39(6):788-93. PubMed ID: 17129417
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulatory type A CpG-DNA induces a Th2-like response in human endothelial cells.
    Fitzner N; Zahner L; Habich C; Kolb-Bachofen V
    Int Immunopharmacol; 2011 Nov; 11(11):1789-95. PubMed ID: 21820085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid Nanoparticle Delivery Alters the Adjuvanticity of the TLR9 Agonist CpG by Innate Immune Activation in Lymphoid Tissue.
    Zhong Z; Chen Y; Deswarte K; Lauwers H; De Lombaerde E; Cui X; Van Herck S; Ye T; Gontsarik M; Lienenklaus S; Sanders NN; Lambrecht BN; De Koker S; De Geest BG
    Adv Healthc Mater; 2023 Dec; 12(32):e2301687. PubMed ID: 37772637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG oligodeoxynucleotides and mobilization of innate mucosal immunity: tasks and tactics.
    Harandi AM; Holmgren J
    Vaccine; 2006 Apr; 24 Suppl 2():S2-48-9. PubMed ID: 16823923
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Toll-Like Receptor 21 of Chicken and Duck Recognize a Broad Array of Immunostimulatory CpG-oligodeoxynucleotide Sequences.
    Chuang YC; Tseng JC; Yang JX; Liu YL; Yeh DW; Lai CY; Yu GY; Hsu LC; Huang CM; Chuang TH
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33147756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
    Schetter C; Vollmer J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
    Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
    Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNA motifs suppressing TLR9 responses.
    Trieu A; Roberts TL; Dunn JA; Sweet MJ; Stacey KJ
    Crit Rev Immunol; 2006; 26(6):527-44. PubMed ID: 17341193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides.
    Klinman DM; Zeuner R; Yamada H; Gursel M; Currie D; Gursel I
    Ann N Y Acad Sci; 2003 Dec; 1002():112-23. PubMed ID: 14751829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo.
    Schlaepfer E; Audigé A; von Beust B; Manolova V; Weber M; Joller H; Bachmann MF; Kundig TM; Speck RF
    J Virol; 2004 Nov; 78(22):12344-54. PubMed ID: 15507621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CpG-oligodeoxynucleotides developed for grouper toll-like receptor (TLR) 21s effectively activate mouse and human TLR9s mediated immune responses.
    Yeh DW; Lai CY; Liu YL; Lu CH; Tseng PH; Yuh CH; Yu GY; Liu SJ; Leng CH; Chuang TH
    Sci Rep; 2017 Dec; 7(1):17297. PubMed ID: 29229937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three CpG oligodeoxynucleotide classes differentially enhance antigen-specific humoral and cellular immune responses in mice.
    Liu Y; Luo X; Yang C; Yu S; Xu H
    Vaccine; 2011 Aug; 29(34):5778-84. PubMed ID: 21664398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progress in drug development of immunostimulatory CpG oligodeoxynucleotide ligands for TLR9.
    Vollmer J
    Expert Opin Biol Ther; 2005 May; 5(5):673-82. PubMed ID: 15934842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuning CpG motif position in nanostructured DNA for efficient immune stimulation.
    Tan M; Makiguchi N; Kusamori K; Itakura S; Takahashi Y; Takakura Y; Nishikawa M
    Biotechnol J; 2024 Apr; 19(4):e2300308. PubMed ID: 38651249
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CpG oligodeoxynucleotides as DNA adjuvants in vertebrates and their applications in immunotherapy.
    Chaung HC
    Int Immunopharmacol; 2006 Oct; 6(10):1586-96. PubMed ID: 16919831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of new CpG oligodeoxynucleotide motifs that induce expression of interleukin-1β and nitric oxide in avian macrophages.
    Sanjaya A; Elder JR; Shah DH
    Vet Immunol Immunopathol; 2017 Oct; 192():1-7. PubMed ID: 29042009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiinfective applications of toll-like receptor 9 agonists.
    Krieg AM
    Proc Am Thorac Soc; 2007 Jul; 4(3):289-94. PubMed ID: 17607015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.